The Viper ultrasonic pharmacomechanical thrombolysis system is an INVAMED device engineered to combine targeted ultrasonic energy with controlled thrombolytic infusion. This overview describes the platform's design intent for clinicians evaluating ultrasound-assisted approaches to DVT and venous thrombus management.
What Is the Viper Ultrasonic Pharmacomechanical Thrombolysis System?
Viper is a minimally invasive catheter system designed to dissolve thrombus by pairing low-power ultrasonic waves with localized infusion of a thrombolytic agent such as tPA. The system uses an infusion catheter with a multi-hole design intended to distribute thrombolytic medication uniformly across extended clot segments, rather than concentrating drug delivery at a single point.
How Is the Ultrasonic Mechanism Designed to Work?
The ultrasonic component is intended to focus low-power energy on fibrin disruption within the thrombus. By loosening the structural integrity of fibrin strands, the ultrasonic action is designed to help the thrombolytic agent penetrate more deeply into the clot, supporting more thorough thrombus dissolution than drug infusion alone. The energy levels used are calibrated with the intent of minimizing effects on surrounding valves, vessel walls, and other critical structures within the venous or pulmonary vasculature.
What Are the Key Technical Specifications?
- Configuration — over-the-wire catheter design
- Catheter lengths — available in 90 cm, 135 cm, 150 cm, and 200 cm, supporting access to varied venous targets including, in appropriate clinical contexts, the pulmonary artery
- Infusion design — multi-hole catheter intended for uniform thrombolytic distribution across the clot segment
- Combined mechanism — ultrasonic energy paired with pharmacologic thrombolytic infusion
What Are the Intended Clinical Benefits of This Approach?
By combining ultrasonic-assisted fibrin disruption with localized drug delivery, the Viper system is designed to support a treatment strategy that may allow for lower overall thrombolytic dosing compared to standard systemic delivery, which can be a relevant consideration for bleeding risk management. As with all thrombolytic-based therapies, actual dosing, infusion duration, and patient selection are determined by the treating physician based on individualized clinical judgment and the official Instructions for Use (IFU).
Frequently Asked Questions
How does ultrasonic-assisted thrombolysis differ from standard CDT?
Standard catheter-directed thrombolysis relies solely on localized drug infusion, while ultrasonic-assisted systems like Viper add calibrated ultrasonic energy intended to help disrupt fibrin structure, which is designed to support more effective drug penetration into the clot.
Is the Viper system used for pulmonary embolism as well as DVT?
Viper's catheter length options are designed to support access to a range of venous targets. Specific indications for pulmonary or venous use should be confirmed against the current IFU and determined by the treating physician.
Does ultrasonic energy pose additional risk to the vessel wall?
The system's ultrasonic energy is calibrated with the intent of minimizing impact on vessel walls and valves. As with any endovascular procedure, risks exist, and appropriate technique per the IFU is important to safe use.
Related INVAMED Resources
- Deep Vein Thrombosis (DVT) Product Portfolio
- Pulmonary Embolism Management
- Request Information from INVAMED
Medical Disclaimer: This article is provided for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It is not a substitute for consultation with a qualified healthcare professional. Product indications, availability, and regulatory status vary by country. Always refer to the official Instructions for Use (IFU) and consult a licensed physician for guidance specific to your situation. INVAMED devices are intended for use by trained healthcare professionals.